AMMC Approves Laprophan's IPO at 2.22 Billion MAD
The Moroccan Capital Market Authority (AMMC) has officially approved the prospectus for Laprophan's initial public offering (IPO), a significant event for the pharmaceutical sector in Morocco. This IPO is set to take place from November 9 to November 17, 2026, with a subscription price established at 341 MAD per share, excluding specific discounts allocated to the company's employees and executives. Laprophan intends to issue 4,105,500 new shares while potentially offering up to 2,412,200 existing shares for sale. The total maximum amount expected from this operation, including the issuance premium, could surpass 2.22 billion MAD, marking a substantial milestone in the Moroccan financial landscape.
The AMMC has indicated that the shares will be listed on the primary compartment A of the Casablanca Stock Exchange, which further underscores the importance of this IPO for investors and stakeholders alike. The approval was granted following a meeting of Laprophan's ordinary and extraordinary general assembly on October 26, where the decision to proceed with the IPO was unanimously supported.
The prospectus not only includes the reference document for the 2025 fiscal year and the first half of 2026 but also a detailed operational note outlining the IPO procedures. Interested parties can access these documents through the websites of Laprophan, the AMMC, and the Casablanca Stock Exchange, as well as at the company's headquarters and from members of the placement syndicate.
What’s Next for Laprophan?
As Laprophan prepares for its IPO, it is noteworthy that the company is also poised to acquire 100% of Polymedic, which could further enhance its market position. This strategic move, alongside the IPO, demonstrates Laprophan's commitment to growth and development within the pharmaceutical sector in Morocco. Investors are keenly watching this unfolding scenario, as it represents a pivotal moment for both Laprophan and the Moroccan market as a whole.
As reported by h24info.ma.
